Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Introduction for sexuality after prostate cancer

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.


  1. 1.

    Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424.

    Article  Google Scholar 

  2. 2.

    Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, et al. EAU guidelines on prostate cancer. part 1: screening, diagnosis, and local treatment with curative intent-update 2013. Eur Urol. 2014;65:124–37.

    Article  Google Scholar 

  3. 3.

    Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, et al. EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol. 2014;65:467–79.

    CAS  Article  Google Scholar 

  4. 4.

    Donovan JL, Hamdy FC, Lane JA, Mason M, Metcalfe C, Walsh E, et al. Patient-reported outcomes after monitoring, surgery, or radiotherapy for prostate cancer. N Engl J Med. 2016;375:1425–37.

    CAS  Article  Google Scholar 

  5. 5.

    Fode M, Mosholt KS, Nielsen TK, Tolouee S, Giraldi A, Østergren PB, et al. Sexual motivators and endorsement of models describing sexual response of men undergoing androgen deprivation therapy for advanced prostate cancer. J Sex Med. 2020;17:1538–43.

    Article  Google Scholar 

  6. 6.

    Fode M, Serefoglu EC, Albersen M, Sønksen J. Sexuality following radical prostatectomy: is restoration of erectile function enough? Sex Med Rev. 2017;5.

  7. 7.

    Morgentaler A, Caliber M. Safety of testosterone therapy in men with prostate cancer. Expert Opin Drug Saf. 2019;18:1065–76.

    CAS  Article  Google Scholar 

Download references

Author information



Corresponding author

Correspondence to Mikkel Fode.

Ethics declarations

Conflict of interest

Mikkel Fode is a speaker for Astellas Pharma and an advisor for Ferring Pharmaceuticals.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Fode, M. Introduction for sexuality after prostate cancer. Int J Impot Res 33, 389–390 (2021).

Download citation


Quick links